Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study

Cancers (Basel) · 2026 · PMC13297090

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

only marginally significantno p-value reported

In this pooled analysis, the survival benefit of ICIs was only marginally significant (HR 0.84, 95% CI 0.70–1), and no pooled results were available by cancer type.

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.